BRITISH MEDICAL BULLETIN

VOLUME THIRTY-EIGHT
1982

Number 1. ALCOHOL AND DISEASE

Scientific Editor . . . . . S SHERLOCK

★

Number 2. MALARIA

Scientific Editor . . . . . S COHEN

★

Number 3. REGULATORY PEPTIDES OF GUT AND BRAIN

Scientific Editor . . . . . R A GREGORY

★

ISSN: 0007-1420

CHURCHILL LIVINGSTONE · 5 BENTINCK STREET · LONDON · W1M 5RN

CONTENTS OF NUMBER 1

		PAGE
Introduction	*Sheila Sherlock*	1
Epidemiology of alcohol use and its hazards: with a note on screening methods	*Jonathan Chick*	3
Alcohol and disease: economic aspects	*R Weeden & A Burchell*	9
Histocompatibility antigens in alcoholic liver disease	*Adrian L W F Eddleston & Michael Davis*	13
Ethanol metabolism	*T J Peters*	17
Alcohol and nutrition	*Marsha Y Morgan*	21
Alcohol and cancer	*Roderick N M MacSween*	31
Alcohol and the endocrine system	*Marsha Y Morgan*	35
Sex, alcohol and the developing fetus	*Marsha Y Morgan & O E Pratt*	43
Alcoholic muscle disease	*F C Martin, G Slavin & A J Levi*	53
Alcohol and the pancreas	*G Lake-Bakaar*	57
The morphology of alcoholic liver disease	*Peter J Scheuer*	63
Alcohol-related liver disease: clinical aspects and management	*Sheila Sherlock*	67
Alcohol and the gastrointestinal tract	*M J S Langman & G D Bell*	71
Alcohol and the heart	*Edwin L Alderman & D John Coltart*	77
Haemopoiesis and alcohol	*I Chanarin*	81
Alcohol-related brain damage	*Allan D Thomson & Maria A Ron*	87
Objective psychological changes in alcoholics after the withdrawal of alcohol	*W Acker*	95
Alcohol dependence and withdrawal	*G K Shaw*	99
Treatment of alcohol dependence: the alcoholic patient	*P W Brunt*	103
Treatment of alcohol dependence: long-term treatment of the psychological effects	*M M Glatt*	106

Notes on Contributors 109 Index 113

CONTENTS OF NUMBER 2

		PAGE
Introduction	*I A McGregor*	115
The life-cycle of primate malaria parasites	*R S Bray & P C C Garnham*	117
Genetic variation in malaria parasites	*D Walliker*	123
Cultivation of malaria parasites	*W Trager*	129
The interaction of malaria parasites with red blood cells	*G Pasvol & R J M Wilson*	133
New knowledge of parasite morphology	*L H Bannister & R E Sinden*	141
The anaemia of *Plasmodium falciparum* malaria	*D J Weatherall & S Abdalla*	147
Immunity to malaria	*J H L Playfair*	153
Progress in malaria vaccine development	*Sydney Cohen*	161
Malaria and alterations in immune reactivity	*W P Weidanz*	167
Immunodiagnosis and sero-epidemiology of malaria	*A Voller & C C Draper*	173
Imported malaria: an uninvited guest	*L J Bruce-Chwatt*	179
Antimalarial drug resistance: an increasing problem	*W Peters*	187
Advances in chemotherapy	*R E Howells*	193
Developments in malaria vector control	*G Davidson*	201
Malaria vector ecology and genetics	*G B White*	207

Notes on Contributors 213 Index 217

CONTENTS OF NUMBER 3

		PAGE
Introduction	*R A Gregory*	219
The APUD concept: where has it led us?	*Ann Andrew*	221
Evolutionary and comparative aspects of gut and brain peptides	*E J W Barrington*	227
Clinical aspects of gut hormones and neuropeptides	*Stephen R Bloom & Julia M Polak*	233
Neurotensin	*David R Brown & Richard J Miller*	239
Neuronal peptides in the intestine	*M Costa & J B Furness*	247
The physiology of cholecystokinin in brain and gut	*G J Dockray*	253
Neurochemical pathology of brain peptides	*J A Edwardson & J R McDermott*	259
Vasoactive intestinal polypeptide: functional aspects	*Jan Fahrenkrug & Piers C Emson*	265
Heterogeneity of gut and brain regulatory peptides	*R A Gregory*	271
Substance P	*L L Iversen*	277
Electrophysiology of peptides in the central nervous system	*J S Kelly*	283
Electrophysiology of peptides in the peripheral nervous system	*R A North & T M Egan*	291
Mechanisms of action of hormonal and neuronal peptides on exocrine gland cells	*O H Petersen*	297
Localization of regulatory peptides in the gut	*Julia M Polak & Stephen R Bloom*	303
Coexistence of amines and peptides in the central and peripheral nervous systems	*Marianne Schultzberg, Tomas Hökfelt & Jan M Lundberg*	309

Notes on Contributors 315 Index 317

INDEX TO NUMBER 1

A

Acetaldehyde, effect on developing fetus, 51
—toxicity and oxidation, 18
ACKER W: Objective psychological changes in alcoholics after the withdrawal of alcohol, 95–98
Adrenal cortex, effects of alcohol on, 35, 36, 37
Alcohol, *see also* Ethanol
—and disease; introduction to symposium, 1–2
—and gastrointestinal tract, 71–75
—and nutrition, 21–29
—consumption patterns, 4
——relation to adverse consequences, 5
——screening methods, 7
——trends amongst women, 1, 4
—dependence, mechanism of, 99
——treatment, 103–108
————long-term, psychological effects, 106–108
————physical methods, 108
————psychological methods, 107
—effect on endocrine system, 35–42
——on fetus, 48–52
——on gonadal function, 43–48
——on haemopoiesis, 81–86
——on heart, 77–80
——on pancreas, 57–62
—hazards of use, 3–8
—mode of action in carcinogenesis, 32
—myopathy due to, 53–56
—problem drinking, 6, 7
—toxicity, acute, treatment, 103
—withdrawal, mechanism of, 99–102
——psychological effects in alcoholics, 95–98
——syndromes, management of, 101, 104
Alcohol-related disorders, prevalence, 3
Alcoholics Anonymous, 108
Alcoholism, economic aspects, 9–11
—epidemiology, 3–8
ALDERMAN E L & COLTART D J: Alcohol and the heart, 77–80
Aldosterone metabolism, effects of alcohol on, 37
Amnesia, 87, 88, 91, 98
Anaemia, haemolytic, in alcoholics, 84
—megaloblastic, in alcoholics, 83
—sideroblastic, in alcoholics, 84
Anaesthesia and surgery in alcoholics, 105
Antidiuretic hormone release, effects of alcohol on, 41
Aversion therapy, 108

B

BELL G D, *see* LANGMAN M J S, 71
Biliary secretion in alcoholics, 23
Biographical notes on contributors, 109–111
Blood, abnormalities in alcoholics, 25
—flow, effect of alcohol on, 23
—haemopoiesis, effects of alcoholism, 81–86
Bone-marrow changes in alcoholics, 26, 82
Brain damage due to nutritional deficiency, 87
——intra-uterine, alcohol-related, 50
——syndromes, alcohol-related, 91–94
—structural changes, alcohol-related, 87–91
BRUNT P W: Treatment of alcohol dependence: the alcoholic patient, 103–105
BURCHELL A, *see* WEEDEN R, 9

C

Calcitonin secretion, effects of alcohol on, 39
Cancer, association with alcohol, 31–33
Carbohydrate metabolism, disorders in alcoholics, 55
Cardiomyopathy, congestive, alcohol-related, 77
CHANARIN I: Haemopoiesis and alcohol, 81–86
CHICK J A: Epidemiology of alcohol use and its hazards: with a note on screening methods, 3–8
Cirrhosis, hepatic, *see* Liver, cirrhosis
Cognitive impairment in alcoholics after alcohol withdrawal, 95
Colon, effect of alcohol on, 74
COLTART D J, *see* ALDERMAN E L, 77
Contributors, biographical notes on, 109–111
Convulsions in withdrawing alcoholic, 100
Cushing's syndrome, alcohol-related, 35, 36

D

DAVIS M, *see* EDDLESTON A L W F, 13
Delirium tremens in withdrawing alcoholic, 101
Dementia, alcoholic, 89, 92
Deoxyuridine suppression test, 84
Dependence on alcohol, mechanisms of, 99
——treatment, 103–108
Diabetes and alcoholism, management, 105
Diarrhoea, alcohol-induced, 74

E

EDDLESTON A L W F & DAVIS M: Histocompatibility antigens in alcoholic liver disease, 13–16
Endocrine system, effects of alcohol on, 35–42
Erythrocytes, metabolic disorders in alcoholics, 85
Ethanol, adaptive responses to, 19
—effect on developing embryo, 51
——on small intestinal function, 72–74
——on vitamin absorption, 74
—metabolism, 17–20, 73
—oxidation, redox alterations following, 18
—test meal, 71

F

Fertility, effect of alcohol on, 47, 49
Fetal alcohol syndrome, 49, 50
Fetus, effect of alcohol on, 48–52
Folate concentration and metabolism, 83, 85

G

Gastritis, alcoholic, 71
Gastrointestinal tract, cancer, alcohol-related, 32, 71
——damage, alcohol-related, and malnutrition, 25
——effects of alcohol on, 71–75
Genetic aspects of alcoholism, 13
GLATT M M: Treatment of alcohol dependence: long-term treatment of the psychological effects, 106–108
Glucagon secretion, effects of alcohol on, 40
Gonadotrophin concentration, effects of alcohol on, 44
Gonads, effects of alcohol on, 43–48
Growth hormone secretion, effects of alcohol on, 39

H

Haematemesis, alcohol-related, 72
Haemodynamic changes due to alcohol, 77
Haemopoiesis in alcoholics, 81–86
Haemostasis in alcoholics, 85
Hallucinosis in withdrawing alcoholic, 100
Heart, biochemical changes due to alcohol, 78
—damage, alcohol-related, 25
—disorders, alcohol-related, 6, 77–80
————natural history, 78
—haemodynamic changes due to alcohol, 77
Heartburn and alcohol intake, 71
Hepatitis, alcoholic, acute, 67, 69
——differential diagnosis, 64
——histocompatibility antigens in, 13–16
——morphology, 64
Hepatocellular carcinoma in alcoholics, 64
Histocompatibility antigens in alcoholic liver disease, 13–16
Hormone systems, effects of alcohol on, 35–42, 43
Hyperglycaemia, alcohol-related, 41
Hyperoestrogenism, alcohol-related, 43–48
Hypoglycaemia, alcohol-related, 40
Hypogonadism, alcohol-related, 43–48
Hypothalamus, effects of alcohol on, 35, 36, 43

I

Immune system in alcoholics, 13, 26
Infertility, alcohol-related, 47, 49
Insulin secretion effects of alcohol on, 40
Intestine, small, bacterial overgrowth in alcoholics, 24
——effects of alcohol on, 72
Iron storage in alcoholics, 85

INDEX TO NUMBER 1

K

Korsakoff's psychosis, 26, 87–89, 91–94

L

LAKE-BAKAAR G: Alcohol and the pancreas, 57–62
LANGMAN M J S & BELL G D: Alcohol and the gastrointestinal tract, 71–75
Leucocytes in alcoholics, 83
LEVI A J, *see* MARTIN F C, 53
Liver, cancer, relation to alcohol intake, 32, 46, 70
—cirrhosis, and hepatocellular carcinoma, 64
———established, clinical features, 68
———prognosis, 70
———histocompatibility antigens in, 13–16
———mortality, 3
———steatorrhoea in, 24
—disease, alcohol-related, 67–70
———and malnutrition, 25
———association with histocompatibility antigens, 13–16
———clinical features, 67
———diagnosis, 68
———early recognition, 67, 69
———management, 69
———morphology, 63–65
———prognosis, 70
—fatty, 63
—storage in alcoholics, 24
Longevity, relation to alcohol consumption, 6
Luteinizing hormone secretion in alcoholics, 44
Lymphocytes in alcoholics, 83

M

Macrocytosis of alcoholism, 81
MACSWEEN R N M: Alcohol and cancer, 31–33
Malabsorption in alcoholics, 22, 23
—mechanisms, 23
Malnutrition in alcoholics, 21–29
—aetiology, 21
—and tissue injury, 25, 87
—recognition and treatment, 26, 105
MARTIN F C, SLAVIN G & LEVI A J: Alcoholic muscle disease. 53–56
Megaloblastosis in alcoholics, 82
Melaena, alcohol-related, 72
Memory impairment in non-Korsakoff alcoholics after alcohol withdrawal, 96
Metabolism of nutrients, impairment by alcohol, 24
MORGAN M Y: Alcohol and nutrition, 21–29
—Alcohol and the endocrine system, 35–42
—Sex and alcohol, 43–48
Mouth, cancer, relation to alcohol intake, 31
Muscle disease, alcoholic, 53–56

N

Nervous system, alcohol-related damage, 26, 87
Neurological disease, relation to nutritional deficiency, 87
Neuropathy, peripheral, due to alcohol, 90
Neuropsychiatric disability, neonatal, alcohol-related, 50
Neuroradiological abnormalities in chronic alcoholics, 93
Nutrient requirements in alcoholics, 24
Nutrition, effects of alcoholism on, 21–29

O

Oesophagus, cancer, relation to alcohol intake, 31, 71
—effect of alcohol on, 71
Oestradiol concentration, effects of alcohol on, 44
Oestrogen secretion, effects of alcohol on, 44, 46

P

Pancreas, effects of alcohol on, 57–62
Pancreatic secretion in alcoholics, 23, 24
Pancreatitis, chronic, alcoholic, clinical features, 59
———diagnosis, 59
———epidemiology, 57
———pathogenesis, 58
———prognosis, 61
———treatment, 60
Parathormone secretion, effects of alcohol on, 39
Peptic ulcer and alcohol intake, 72
PETERS T J: Ethanol metabolism, 17–20
Pharynx, cancer, relation to alcohol intake, 31
Pituitary, effects of alcohol on, 35, 36, 43
Pneumoencephalography studies in chronic alcoholics, 93
PRATT O E: Alcohol and the developing fetus, 48–52
Problem drinking, 6, 7
Psychological changes in alcoholics after alcohol withdrawal, 95–98

R

Rhabdomyolysis, acute, 53
RON M A: Syndromes of alcohol-related brain damage, 91–94

S

SCHEUER P J: The morphology of alcoholic liver disease, 63–65
Sex disorders, alcohol-related, 43–48
SHAW G K: Alcohol dependence and withdrawal, 99–102
SHERLOCK S: Alcohol and disease. Introduction to symposium, 1–2
—Alcohol-related liver disease: clinical aspects and management, 67–70
SLAVIN G, *see* MARTIN F C, 53
Steatorrhoea in alcoholics, 23, 24
Stomach, effect of alcohol on, 71

T

Testosterone secretion, effects of alcohol on, 44, 46
Thiamine deficiency and brain damage, 88
THOMSON A D: Alcohol-related structural brain changes, 87–91
Thyroid, effects of alcohol on, 37, 38
Tomography, computer-assisted, in chronic alcoholics, 93
Tremulousness in withdrawing alcoholic, 100

V

Vitamin B_{12}, 84
—deficiencies in alcoholics, 26, 55, 87

W

WEEDEN R & BURCHELL A: Alcohol and disease: economic aspects, 9–11
Wernicke's encephalopathy, 26, 87–89, 91–94

INDEX TO NUMBER 2

A

ABDALLA S, *see* WEATHERALL D J, 147
Air travel and malaria importation, 179
Anaemia of *P. falciparum* malaria, 147–151
———mechanisms, 148
———patterns, 148
Alloantigens, response to, suppression due to malaria, 168
4-Aminoquinolines, resistance to, 189
Anopheles, bionomics, 207
—cytogenetics, 210
—ecological polymorphism, 211
—species complexes, 208–210
Antibodies, malaria-specific, 156
—malarial, detection and measurement, 173
—non-malaria-specific, 155
Antibody formation, suppression in malaria, 167
Antifols, 196
—resistance to, 188
Antigens, malarial, detection and measurement, 173
—of blood-stage parasites, 163
Antimalarial drugs, in-vitro testing, 194
——in-vivo testing, 193
——long-acting, 197
——resistance to, 187–192

B

BANNISTER L H & SINDEN R E: New knowledge of parasite morphology, 141–145
Biographical notes on contributors, 213–215
BRAY R S & GARNHAM P C C: The life-cycle of primate malaria parasites, 117–122
BRUCE-CHWATT L J: Imported malaria: an uninvited guest, 179–185

C

Chemotherapy of malaria, 193–199
——drug resistance, 187–192
Chloroquine, 194
—resistance in malaria parasites, 126, 189, 190
Clociguanil, 196
—resistance to, 189
COHEN S: Progress in malaria vaccine development, 161–165
Contributors, biographical notes on, 213–215
Cycloguanil, 198
—resistance to, 189

D

Dabequine, 196
DAVIDSON G: Developments in malaria vector control, 201–206
DRAPER C C, *see* VOLLER A, 173
Drug resistance in malaria, 187–192
—response in malaria, assay techniques, 187, 188
Duffy antigen as receptor for malaria parasite, 133

E

Erythrocytes, age in relation to susceptibility to invasion by malaria parasite, 135
—defective production in malaria, 150
—destruction in malaria, 148
——role of immunity, 149
—disorders implicated in protection against *P. falciparum* malaria, 137–139
—interaction of malaria parasites with, 133–140
—invasion by *P. falciparum*, pattern, 147
—malaria parasite entry into, 134
———growth in, 136
—*P. falciparum* receptors on, 134
Erythrocytic stages of malaria parasite, 143, 144
——vaccination against, 162
Erythropoiesis, defective, in malaria, 150
Exoerythrocytic stages of malaria parasite, 117, 142
——vaccination against, 161

F

Fansidar, 194
—resistance to, 189, 195
Floxacrine, 196

G

Gametocytes, 144
—production in vitro, 130
GARNHAM P C C, *see* BRAY R S, 117
Genetic variation in malaria parasites, 123–128
Glucose-6-phosphate dehydrogenase deficiency and malaria, 138

H

Haemoglobin E, 139
—F, 138
—S, 137
HOWELLS R E: Advances in chemotherapy, 193–199
Hydroxypiperaquine phosphate, 196
Hypnozoites, 117, 120

I

Immune response, cell-mediated, suppression due to malaria infection, 168
——parasite-specific, suppression, 168
Immunity to malaria, 153–159
Immunosuppression due to malaria, 167–172
Immunodiagnosis and sero-epidemiology of malaria, 173–177
Immunofluorescence for malarial antibody determination, 175
Immunoglobulin levels in malaria, 154
Immunopathology, 157
Immunosuppression, 167–172
—mechanisms, 169
Insecticides, antimalarial, 201
—resistance to, 203

L

Larvicides, 203
Laverania falciparum, special features, 121
Life-cycle of primate malaria parasites, 117–122

M

McGREGOR I A: Malaria. Introduction to symposium, 115–116
Malaria, 115–215
—and increased susceptibility to concurrent infection, 169
—antibodies, detection and measurement, 173
——response, 155
—antigens, detection and measurement, 173
——variations, 127
—chemotherapy, 193–199
—drug response, assay techniques, 187, 188
—immune complexes, 156
——reactivity in, alterations, 167–172
—immunity, 153–159
——acquired, 153, 154
——evasion by parasites, 157
——natural, 153
———mechanisms, 154
——T-cell-mediated, 156
—immunodiagnosis, 173–177
—immunopathology, 157
—immunosuppression due to, 167–172
——mechanisms, 169
—importation in Europe, 180
——in United Kingdom, 181
—imported, 179–185
——surveillance of, 184
—in pregnancy, 157
—introduction to symposium, 115–116
—parasites, breeding structure, 124
——causing relapses, 118
——cultivation, 129–131
——cycle in blood, 117
——development in anopheline mosquitoes, 118
——drug sensitivity, variations, 126
——enzyme variation, 124
——erythrocytic stages, 143–144
——exoerythrocytic stages, 142
———in-vitro cultivation, 131
——genetic variation, 123–128
——genome, organization, 124
——growth inside red cells, 136
——host-cell preference, 127
——interaction with red blood cells, 133–140

Malaria, parasites, continued
——life-cycle, 117–122
——morphology, 141–145
——virulence, variations, 127
—sero-epidemiology, 173–177
—serology, epidemiological applications, 176
——in non-endemic areas, clinical application, 175
—splenectomy in, effects, 156
—vaccination procedures, 161–165
—vector control, 201–206
——ecology, 207–210
——environmental management, 204
——genetics, 210–212
Mefloquine, 195
Merozoites, 117, 143
—vaccines, 162
Mitogens, response to, suppression due to malaria, 168
Mosquito, biological control, 205
—control methods, 201–206
—cytogenetics, 210
—environmental control, 204
—genetic control, 205

O

Oöcyst, 141
Oökinete, 141
Ovalocytosis, 139

P

Parasites, morphology, 141–145
PASVOL G & WILSON R J M: The interaction of malaria parasites with red blood cells, 133–140
PETERS W: Antimalarial drug resistance: an increasing problem, 187–192
Phenanthrenemethanols, 196
Plasmodium cynomolgi and subspecies, special features, 122
—*falciparum* drug resistance, 187, 190
——enzyme forms, 125
——genetic variation, 125
——malaria, anaemia of, 147–151
——prophylaxis, red-cell disorders implicated in, 137–139
——red-cell receptors, 134
——special features, 121
—immunodepression due to, 167–172
—*knowlesi*, special features, 122
—*malariae*, special features, 121
—morphology, 141–145
—*ovale*, special features, 121
—vector susceptibility, genetics of, 210
—*vivax*, special features, 121
PLAYFAIR J H L: Immunity to malaria, 153–159
Pregnancy, effect on malaria, 157
Primaquine, 194, 197
—role in malaria therapy, 191
Primate malaria parasites, life-cycle, 117–122
Proguanil, resistance to, 189
Pyridinemethanols, 196
Pyrimethamine, 194
—resistance in malaria parasites, 126, 189

Q

Qinghaosu, 197
Quinine, resistance to, 190
Quinolinemethanols, 196

S

Schizogony, exoerythrocytic, of malaria parasite, 117
Schizontocidal compounds, blood, 194–197
——tissue, 197
Schizonts, 143
SINDEN R E, *see* BANNISTER L H, 141
Spherocytosis, 139
Splenectomy in malaria, effects, 156
Splenomegaly syndrome, tropical, 157
Sporozoites, 142
—antigens, 162
—introduction during malaria infection, 117
—vaccines, 161

T

T-cell-mediated immunity in malaria, 156
Thalassaemia, 139
TRAGER W: Cultivation of malaria parasites, 129–131
Trophozoites, 143

V

Vaccination against malaria, 161–165
—against sexual forms of parasite, 164
Vector, capacity, 211
—control, 201–206
——alternatives to chemicals, 204–206
—ecology, 207–210
—genetics, 210–212
VOLLER A & DRAPER C C: Immunodiagnosis and sero-epidemiology of malaria, 173–177

W

WALLIKER D: Genetic variation in malaria parasites, 123–128
WEATHERALL D J & ABDALLA S: The anaemia of *Plasmodium falciparum* malaria, 147–151
WEIDANZ W P: Malaria and alterations in immune reactivity, 167–172
WHITE G B: Malaria vector ecology and genetics, 207–212
WILSON R J M, *see* PASVOL G, 133

Z

Zygote, 141

INDEX TO NUMBER 3

A

Acetylcholine, coexistence with vasoactive intestinal polypeptide, 269
Adrenocorticotrophic hormone, electrophysiology in central nervous system, 283
Alzheimer's disease, peptide concentrations in, 262
Amine precursor uptake and decarboxylation concept, 221–225
Anaemia, pernicious, effect on gut hormone secretion, 234
ANDREW A: The APUD concept: where has it led us?, 221–225
Angiotensin II, electrophysiology in central nervous system, 283
———electrophysiology in peripheral nervous system, 292
Antinociception, neurotensin-induced, 241
APUD cells, common origin, 223
—concept, 221–225
—tumours, progenitor cells, origin of, 224

B

BARRINGTON E J W: Evolutionary and comparative aspects of gut and brain peptides, 227–232
Biographical notes on contributors, 315–316
BLOOM S R & POLAK J M: Clinical aspects of gut hormones and neuropeptides, 233–238
—*see* POLAK J M, 303
Bombesin, actions on pancreatic acini, 298
—electrophysiology in central nervous system, 284
—gastrin-releasing peptide, 252
Bowel disorders, effect on gut hormone secretion, 235, 236
Bradykinin, electrophysiology in central nervous system, 284
Brain, cholecystokinins, physiology, 253–258
—peptide concentrations in, 262
—peptides, electrophysiology, 283–290
———evolutionary and comparative aspects, 227–232
———heterogeneity, 271–276
———introduction to symposium, 219–220
———neurochemical pathology, 259–264
———*see also* Neuropeptides.
—proteins, localization in gut, 304
Bronchus, carcinoma, gut hormone production in, 237
BROWN D R & MILLER R J: Neurotensin, 239–245

C

Caerulein, electrophysiology in central nervous system, 284
—evolutionary and comparative aspects, 228
Cerebrospinal fluid, neuropeptides in, 261, 262
Chagas' disease, neuropeptides in, 236
Cholecystokinin, 252
—action on exocrine gland cells, 297
—as gut hormone, 256
—as neurotransmitter, 257
—biosynthesis, 254
—cellular origins and release, 254
—central nervous system action, 257
—characterized forms, 253
—electrophysiology in central nervous system, 284
—evolutionary and comparative aspects, 228
—immunochemical studies, 253
—in brain and gut, chemical relationships, 253
—receptors, 255
—satiety action, 257
Cholecystokinin-8, 253–258
Cholecystokinin-33, 253–257
Cholecystokinin-39, 253
Coeliac disease, effect on gut hormone secretion, 234
Colon, function, role of vasoactive intestinal polypeptide, 269
Contributors, biographical notes on, 315–316
COSTA M & FURNESS J B: Neuronal peptides in the intestine, 247–252

D

Diabetes, effect on gut hormone release, 235
Diarrhoea, effect on gut hormone levels, 235
DOCKRAY G J: The physiology of cholecystokinin in brain and gut, 253–258
Dumping syndrome, 233

E

EDWARDSON J A & McDERMOTT J R: Neurochemical pathology of brain peptides, 259–264
EGAN T M, *see* NORTH R A, 291
EMSON P C, *see* FAHRENKRUG J, 265
Endocrine cells, intestinal, peptides in, 222
———relationship with neurones, 222
———types, subclassification, 306
Enkephalin, 231, 251
—electrophysiology in peripheral nervous system, 292, 293
Enkephalinase, 260
Enolase, neurone-specific, 223, 304
Enteroglucagon, 233, 234
Exocrine gland cells, as models for studying mechanism of action of regulatory peptides, 301
———mechanisms of action of hormonal and neuronal peptides on, 297–302

F

FAHRENKRUG J & EMSON P C: Vasoactive intestinal polypeptide: functional aspects, 265–270
Fibrosis, cystic, effect on gut hormone secretion, 235
FMRFamide, electrophysiology in central nervous system, 286
FURNESS J B, *see* COSTA M, 247

G

Gastric secretion, effect of neurotensin on, 242
Gastrin, amino-terminal fragments, 275
—heterogeneity, 273
—translation product, 275
Gastrin–cholecystokinin peptides, actions on exocrine gland cells, 297
Gastrin–cholecystokinin–caerulein group of hormones, 228
Gastrinoma, 237
Gastrointestinal disorders, effect on gut hormone secretion, 235, 236
—tract, effects of neurotensin on, 242
———neuropeptides, clinical aspects, 233–236
———peptides, heterogeneity, 271–276
———localization, 303–307
———resection, gut hormone response, 234
Glicentin, 233
Glucagon, localization of molecular forms, 306
Glucagonoma, 236
GREGORY R A: Heterogeneity of gut and brain regulatory peptides, 271–276
—Regulatory peptides of gut and brain. Introduction to symposium, 219–220
Gut, *see also* Intestine.
—cholecystokinins, physiology, 253–258
—hormone changes in newborn, 235
———clinical aspects, 233–236
———effects of alimentary tract surgery, 233
———effects of inflammatory conditions on, 234
———tumours producing, 236
—neuropeptides, 247–252
———clinical aspects, 233–236
—peptides, evolutionary and comparative aspects, 227–232
———heterogeneity, 271–276
———introduction to symposium, 219–220
———localization, 303–307

H

Hirschsprung's disease, neuropeptides in, 236
HÖKFELT T, *see* SCHULTZBERG M, 309
Hormones, gut, clinical aspects, 233–236
—peptide, gene duplication in, 228
Huntington's disease, neuropeptide levels in, 263
5-Hydroxytryptamine, coexistence with substance P, 278
Hypercholesterolaemia, neurotensin-induced, 243
Hyperglycaemia, neurotensin-induced, 243
Hypothalamus, hormone release, effect of neurotensin, 241
Hypothermia due to neurotensin, 240

I

Immunocytochemistry, electron, in localization of regulatory peptides, 305
Immunogold staining procedure for localization of peptides in gut, 305
Insulinoma, 237
Intestinal ion transport, effect of neurotensin on, 243
Intestine, neuropeptides, 247–252
———action 249
———detection, 249
—resection, gut hormone response, 234
—small, function, role of vasoactive intestinal polypeptide, 268
IVERSEN L L: Substance P, 277–282

K

KELLY J S: Electrophysiology of peptides in the central nervous system, 283–290
Kidney failure, metabolic effects on release of gut hormones, 235

L

Liver failure, metabolic effects on release of gut hormones, 235
LUNDBERG J M, *see* SCHULTZBERG M, 309
Luteinizing-hormone-releasing hormone, electrophysiology in central nervous system, 286
———electrophysiology in peripheral nervous system, 291

M

McDERMOTT J R, *see* EDWARDSON J A, 259
Malabsorption, tropical, effect on gut hormone secretion, 234
Mast cells, influence of neurotensin on, 243
MILLER R J, *see* BROWN D R, 239
Minigastrin, 274
Monoamines, role in APUD concept, 221
Motilin, electrophysiology in central nervous system, 286
—level after intestinal resection, 234
Muscle, smooth, effects of neurotensin in, 242

N

Neurones, afferent autonomic, electrophysiology in peripheral nervous system, 292
—efferent autonomic, electrophysiology, 291
—peptidergic, biochemistry, 259
—peptides in, 222
—relationship with endocrine cells, 222
—somatic, electrophysiology, 291
—visceral autonomic, electrophysiology in peripheral nervous system, 293
Neuropathy, peripheral, neuropeptide levels in, 263
Neuropeptides, biosynthesis, 259
—characterization, 261
—clinical findings, 262
—disposal, 260
—electrophysiology in central nervous system, 283–290
——in peripheral nervous system, 291–296
—intestinal, 247–252
——action, 249
——clinical aspects, 236
——detection, 247
—investigation problems, 261
—localization in gut, 305
—measurement, 261
—mechanism of action on exocrine gland cells, 297–302
—neurochemical pathology, 259–264
—neuronal functions in intestine, 247
—pathological findings, 262
—post-mortem stability, 261
—receptors, 260
—relations to other enteric nerves, 251
—storage and release, 260
Neurotensin, 239–245
—distribution and functions, 239
—effects in central nervous system, 240
——on gastrointestinal smooth muscle, 242
——on peripheral tissues, 242
—electrophysiology in central nervous system, 286
——in peripheral nervous system, 294
—in gastrointestinal tract, 240
—level after intestinal by-pass surgery, 234
—neurochemical effects, 241
—neurotransmitter role, 239
—vascular effects, 242
Neurotensinoma, 237
Neurotransmission, role of vasoactive intestinal polypeptide, 265–270
Neurotransmitters, 222
Newborn, gut hormone changes in, 235
NORTH R A & EGAN T M: Electrophysiology of peptides in the peripheral nervous system, 291–296

O

Oesophagus, vasoactive intestinal polypeptide as neurotransmitter in, 268
Oxytocin, electrophysiology in central nervous system, 287

P

Pancreas, function, role of vasoactive intestinal polypeptide, 269
—secretion, effect of neurotensin on, 242
Pancreatic acini, action of peptides on, 297, 298, 299
Pancreatitis and gut hormone secretion, 235
Paracrine peptides, 222
Parkinson's disease, neuropeptide levels in, 263
Peptic ulcer, gut hormone response to surgical treatment, 233
Peptide, angiotensin-like, 252
—central nervous system, *see* Neuropeptides.
—coexistence with classical transmitters in central and peripheral nervous systems, 309–313
—common to APUD cells and neurones, 222
—development in gut, 304
—in enteric nerves, 303
—gastrin-releasing, 252
—gene duplication in, 228
—gut and brain, evolutionary and comparative aspects, 227–232
————heterogeneity, 271–276
—hormonal, mechanism of action on exocrine gland cells, 297–302
—in gut endocrine cells, 222, 303
—localization in gut, 303–307
—molecules, variants, detection in gut, 306
—neuronal, in intestine, 247–252
——mechanism of action on exocrine gland cells, 297–302
—neurotensin-like, 252
—pancreatic-polypeptide-like, 252
—precursors, 273
—preforms, 273
—regulatory, of gut and brain; introduction to symposium, 219–220
PETERSEN O H: Mechanisms of action of hormonal and neuronal peptides on exocrine gland cells, 297–302
PHI, 306
POLAK J M & BLOOM S R: Localization of regulatory peptides in the gut, 303–307
—*see* BLOOM S R, 233
Polypeptide, gastric inhibitory, after intestinal by-pass surgery, 234
—intestinal, vasoactive, 251
————action on exocrine gland cells, 299
————after gastric surgery, 233
————chemistry, 265
————coexistence with acetylcholine, 269
————distribution, 266
————electrophysiology in central nervous system, 288
————in peripheral nervous system, 294
————function in central nervous system, 267
————in peripheral nervous system, 267
————functional aspects, 265–270
————hypothalamo-pituitary function, 267
————receptors, interaction with adenylate cyclase, 267
————release, 266
————tumours producing, 236
—pancreatic, 231
——secretion after intestinal resection, 234
——tumour secretion, 237
PPoma, 237
PYY, 306

R

Respiratory tract, function, role of vasoactive intestinal polypeptide, 269

S

Salivary acinar cells, actions of substance P peptides on, 300
—secretion, role of vasoactive intestinal polypeptide, 268
Schizophrenia, neuropeptide levels in, 263
SCHULTZBERG M, HÖKFELT T & LUNDBERG J M: Coexistence of classical transmitters and peptides in the central nervous and peripheral nervous systems, 309–313
Secretin, actions on exocrine gland cells, 299
—electrophysiology in central nervous system, 287
—evolutionary and comparative aspects, 230
—peptides, amino acid sequences, 265
Somatostatin, 230, 251
—electrophysiology in central nervous system, 287
——in peripheral nervous system, 294
—in Alzheimer's disease, 262
Somatostatinoma, 237
Sprue, effect on gut hormone secretion, 234
Stomach function, role of vasoactive intestinal polypeptide, 268
—surgery, gut hormone response, 233
Substance P, 231, 251, 277–282
——actions on salivary acinar cells, 300
——antagonists, 281
——as neurotransmitter, 277
——biosynthesis, 280
——coexistence with 5-hydroxytryptamine, 278
——distribution in nervous system, 277
——electrophysiology in central nervous system, 288
————in peripheral nervous system, 292, 293
——metabolism, 280
——receptors in central nervous system, 281
————in peripheral tissues, 280
————study methods, 280

T

Thyrotrophin-releasing hormone, electrophysiology in central nervous system, 288

U

Urogenital tract, function, role of vasoactive intestinal polypeptide, 269

V

Vasopressin, electrophysiology in central nervous system, 289
VIP, *see* Polypeptide, intestinal, vasoactive
VIPoma syndrome, 236

Printed in Great Britain by Spottiswoode Ballantyne Ltd., Colchester and London